A simple, assumption-free, and clinically interpretable approach for analysis of modified Rankin outcomes

George Howard, Jennifer L Waller, Jenifer H Voeks, Virginia J Howard, Edward C Jauch, Kennedy R Lees, Fenwick T Nichols, Volker W Rahlfs, David C Hess, George Howard, Jennifer L Waller, Jenifer H Voeks, Virginia J Howard, Edward C Jauch, Kennedy R Lees, Fenwick T Nichols, Volker W Rahlfs, David C Hess

Abstract

Background and purpose: There is debate regarding the approach for analysis of modified Rankin scale scores, the most common functional outcome scale used in acute stroke trials.

Methods: We propose to use tests to assess treatment differences addressing the metric, "if a patient is chosen at random from each treatment group and if they have different outcomes, what is the chance the patient who received the investigational treatment will have a better outcome than will the patient receiving the standard treatment?" This approach has an associated statement of treatment efficacy easily understood by patients and clinicians, and leads to statistical testing of treatment differences by tests closely related to the Mann-Whitney U test (Wilcoxon Rank-Sum test), which can be tested precisely by permutation tests (randomization tests).

Results: We show that a permutation test is as powerful as are other approaches assessing ordinal outcomes of the modified Rankin scores, and we provide data from several examples contrasting alternative approaches.

Discussion: Whereas many approaches to analysis of modified Rankin scores outcomes have generally similar statistical performance, this proposed approach: captures information from the ordinal scale, provides a powerful clinical interpretation understood by both patients and clinicians, has power at least equivalent to other ordinal approaches, avoids assumptions in the parameterization, and provides an interpretable parameter based on the same foundation as the calculation of the probability value.

References

    1. Saver JL, Gornbein J. Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. Neurology. 2009;72:1310–1315.
    1. Koziol JA, Feng AC. On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I study of NXY-059 for acute ischemic stroke. Stroke. 2006;37:2644–2647.
    1. Saver JL, Gornbein J, Starkman S. Graphic reanalysis of the two NINDS-tPA trials confirms substantial treatment benefit. Stroke. 2010;41:2381–2390.
    1. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke. 2007;38:3055–3062.
    1. Savitz SI, Benatar M, Saver JL, Fisher M. Outcome analysis in clinical trial design for acute stroke: physicians’ attitudes and choices. Cerebrovasc Dis. 2008;26:156–162.
    1. Savitz SI, Lew R, Bluhmki E, Hacke W, Fisher M. Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials. Stroke. 2007;38:3205–3212.
    1. Hill MD, Martin RH, Palesch YY, Tamariz D, Waldman BD, Ryckborst KJ, et al. The Albumin in Acute Stroke Part 1 Trial: An Exploratory Efficacy Analysis. Stroke. 2011;42:1621–25.
    1. den Hertog HM, van der Worp HB, van Gemert HM, Algra A, Kappelle LJ, van Gijn J, et al. The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial. Lancet Neurol. 2009;8:434–440.
    1. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed John Wiley & Sons; New York, NY: 2000. pp. 288–304.
    1. Sinclair JC, Bracken MB. Clinically useful measures of effect in binary analyses of randomized trials. J Clin Epidemiol. 1994;47:881–889.
    1. Agresti A. Analysis of ordinal categorical data. 2nd ed John Wiley & Sons; New York, NY: 2010. pp. 165–176.
    1. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hårdemark HG, Wasiewski WW. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588–600.
    1. The National Institute of Neurological Disorders and Stroke rt-PA stroke study group Tissue plasminogen activator for acute stroke. N Engl J Med. 1995;333:1581–1587.
    1. Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Statist. 1947;22:125–128.
    1. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull. 1945;1:80–83.
    1. Siegel S. Nonparametric statistics for the behavioral sciences. McGraw-Hill Book Company; New York: 1956. pp. 116–127.
    1. Conover WJ. Practical nonparametric statistics. John Wiley and Sons; New York: 1971. pp. 216–223.
    1. Fisher RA. The design of experiments. 8th edition Hafner; New York: 1966. pp. 11–26.
    1. Ludbrook J, Dudley H. Why permutation tests are superior to t and F tests in biomedical research. American Statistician. 1998;52:127–132.
    1. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, et al. Minocyline treatment in acute stroke: an open label, evaluator-blinded study. Neurology. 2007;69:1404–1410.

Source: PubMed

3
Abonnere